Kaken Pharmaceutical Co., Ltd.
October 2, 2018 – Kaken Pharmaceutical Co., Ltd. (“Kaken”, head office Bunkyo-ku, Tokyo; President and Representative Director Tetsuo Onuma) and Main Life Corp., Ltd. (“Main Life”, head office Hong Kong S.A.R., People’s Republic of China; General Manager Ji Ti Jim Wang) announced today that Kaken and Main Life concluded an exclusive distribution agreement for the topical formulation for Onychomycosis “Clenafin / Jublia” (“Product”) in Hong Kong and Macau.
The Product contains efinaconazole, which is new triazole anti-fungal compound discovered by Kaken, as the active ingredient. Efinaconazole has low binding affinity with keratin, the main component of nails, meaning that the Product has superior nail-penetrating properties.
The Product was launched under the trade name of Clenafin in Japan by Kaken in 2014. Overseas, the Product was launched under the trade name of Jublia, in the United States and Canada by Bausch Health Companies Inc. in 2014 and in Korea by Dong-A ST Co., Ltd. in 2017.
According to the agreement, Kaken hereby grants to Main Life the exclusive right for sales of the Product in Hong Kong and Macau. Main Life expects to launch the Product in 2020.
About Main Life
Main Life was established in 1971, has marketed many distinctive Japanese medicinal products in Hong Kong, Macau and Mainland China. Main Life have fully covered all the public and private healthcare sectors including, but not limited to, hospitals, clinics, pharmacies in Hong Kong and Macau. Based on its excellent sales performance and 47 years of experiences of businesses in the region, Main Life aims for the quick penetration of the Product to the utmost throughout the Hong Kong and Macau market.